Thompson Siegel & Walmsley LLC Xeris Biopharma Holdings, Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $6.71 Billion
- Q3 2024
A detailed history of Thompson Siegel & Walmsley LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 172,784 shares of XERS stock, worth $587,465. This represents 0.01% of its overall portfolio holdings.
Number of Shares
172,784
Previous 172,784
-0.0%
Holding current value
$587,465
Previous $389,000
26.48%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding XERS
# of Institutions
143Shares Held
60MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$35.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$26.4 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$17.4 Million62.59% of portfolio
-
Center Book Partners LP Greenwich, CT3.48MShares$11.8 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.33MShares$11.3 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $462M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...